

Drugs@FDA: FDA Approved Drug Products

([https://www.facebook.com/sharer/sharer.php?
u=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?
VERVIEW.PROCESS&APPLNO=020353](https://www.facebook.com/sharer/sharer.php?u=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?VERVIEW.PROCESS&APPLNO=020353))

([https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA Approved Drug S&url=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?
VERVIEW.PROCESS&APPLNO=020353](https://twitter.com/intent/tweet/?text=Drugs@FDA: FDA Approved Drug S&url=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?VERVIEW.PROCESS&APPLNO=020353))

([https://www.linkedin.com/sharearticle?
eUrl=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?
VERVIEW.PROCESS&APPLNO=020353&title=Drugs@FDA: FDA Approved Drug S&source=fda](https://www.linkedin.com/shareArticle?eUrl=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?VERVIEW.PROCESS&APPLNO=020353&title=Drugs@FDA: FDA Approved Drug S&source=fda))

([https://www.pinterest.com/pin/create/button/?
u=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?
VERVIEW.PROCESS&APPLNO=020353&description=Drugs@FDA: FDA Approved Drug S](https://www.pinterest.com/pin/create/button/?u=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?VERVIEW.PROCESS&APPLNO=020353&description=Drugs@FDA: FDA Approved Drug S))

([mailto:?subject=Drugs@FDA: FDA Approved Drug S&body=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?
VERVIEW.PROCESS&APPLNO=020353](mailto:?subject=Drugs@FDA: FDA Approved Drug S&body=https://www.accessdata.fda.gov/scripts/cder/da/index.cfm?VERVIEW.PROCESS&APPLNO=020353))

| [index.cfm](#) | [Previous Page](#)

g Application (NDA): 020353
y: ALVOGEN MALTA

([mailto:?subject=Drugs@FDA: FDA Approved Drug S&body=http://www.accessdata.fda.gov/scripts/cder/da/index.cfm?
VERVIEW.PROCESS%26VARAPPLNO=020353](mailto:?subject=Drugs@FDA: FDA Approved Drug S&body=http://www.accessdata.fda.gov/scripts/cder/da/index.cfm?VERVIEW.PROCESS%26VARAPPLNO=020353))

ation Guide
<http://www.fda.gov/downloads/Drugs/DrugSafety/UCM280324.pdf>

cts on NDA 020353

[/ Excel](#) [Print](#)

g ne	Active Ingredients	Strength	Dosage Form/Route	Marketing Status	TE Code
ELAN	NAPROXEN SODIUM	EQ 375MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB
ELAN	NAPROXEN SODIUM	EQ 500MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB
ELAN	NAPROXEN SODIUM	EQ 750MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription	AB

ng 1 to 3 of 3 entries

[View Date\(s\) and History, Letters, Labels, Reviews for NDA 020353](#) [^](#)**Final Approvals or Tentative Approvals**[/ Excel](#) [Print](#)

on e	Submission	Action Type	Submission Classification	Review Priority; Orphan Status	Letters, Reviews, Labels, Patient Package Insert
1996	ORIG-1	Approval	Type 3 - New Dosage Form	STANDARD	

ng 1 to 1 of 1 entries

Comments[/ Excel](#) [Print](#)

on	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Packa
2017	SUPPL-34	Manufacturing (CMC)-Facility	Label (PDF) (https://www.accessdata.fda.gov/) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_c)
2016	SUPPL-32	Labeling-Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_c) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_c)
2016	SUPPL-31	Labeling-Medication Guide, Labeling-Package Insert	Label (PDF) (https://www.accessdata.fda.gov/drugsatfda_c) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_c)
2014	SUPPL-30	Manufacturing (CMC)	
2011	SUPPL-28	Labeling-Package Insert	Label (PDF) (https://www.accessdata.fda.gov/) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_c)
2009	SUPPL-23	Labeling-Container/Carton Labels, Labeling-Package Insert	Label (PDF) (https://www.accessdata.fda.gov/) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_c)
2007	SUPPL-19	Labeling	Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_c)
2006	SUPPL-16	Labeling	Label (PDF) (https://www.accessdata.fda.gov/) Letter (PDF) (https://www.accessdata.fda.gov/drugsatfda_c)
2002	SUPPL-14	Manufacturing (CMC)-Control	

on	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Packa
2002	SUPPL-8	Labeling	
2001	SUPPL-13	Manufacturing (CMC)	
2001	SUPPL-12	Manufacturing (CMC)-Packaging	
2000	SUPPL-11	Manufacturing (CMC)-Control	
2000	SUPPL-10	Manufacturing (CMC)-Packaging	
1999	SUPPL-7	Manufacturing (CMC)-Control	
1999	SUPPL-9	Manufacturing (CMC)-Packaging	
1997	SUPPL-6	Manufacturing (CMC)-Packaging	

on	Submission	Supplement Categories or Approval Type	Letters, Reviews, Labels, Patient Packa
1997	SUPPL-5	Manufacturing (CMC)-Expiration Date	
1997	SUPPL-4	Manufacturing (CMC)-Expiration Date	
1997	SUPPL-3	Manufacturing (CMC)-Control	
1996	SUPPL-1	Labeling	Review (https://www.accessdata.fda.gov/drugsatfda)

ng 1 to 21 of 21 entries

[View all Submissions for NDA 020353](#)



[View all Therapeutic Equivalents for NDA 020353](#)

